Tomaž Rus

Dr. Tomaž Rus

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 April 2020 in European Journal of Nuclear Medicine and Molecular Imaging
Verified
Journal Article
Closed access
PDF file
TRTomaž Rus
Tomaž Rus
PTPetra Tomše
Petra Tomše
LJLuka Jensterle
Luka Jensterle
MGMarko Grmek
Marko Grmek
ZPZvezdan Pirtošek
Zvezdan Pirtošek
MTMaja Trošt
Maja Trošt

28 July 2022 in Acta Neurologica Scandinavica
Verified
Journal Article
Open access
TRTomaž Rus
Tomaž Rus
MPMaša Premzl
Maša Premzl
NKNina Z. Križnar
Nina Z. Križnar
MKMilica G. Kramberger
Milica G. Kramberger
RRRobert Rajnar
Robert Rajnar
MTMaja Trošt
Maja Trošt
Levodopa/carbidopa intrajejunal gel (LCIG) is an effective therapeutic strategy to overcome levodopa‐induced motor complications in advanced Parkinson's disease (PD). However, it requires invasive percutaneous endoscopic gastrojejunostomy (PEG‐J) and may be associated with serious adverse effects (AE). In this study, we aimed to evaluate long‐term AEs related to LCIG treatment in a large homogenous cohort of advanced PD patients. One hundred three consecutive PD patients were regularly monitored for LCIG‐related, PEG‐J‐related, and device‐related AEs up to 14 years. Incidence of AEs was studied in time applying a time‐to‐event analysis and Cox proportional hazard model with age, disease duration, gender, and recurrent AE as covariates. Health‐related quality of life (HRQoL) was estimated at each visit and compared to HRQoL before the LCIG treatment. Among 296 AEs noted, 48.8% were LCIG‐related, 32.4% PEG‐J‐related, and 19.6% device‐related. While most of the studied AEs steadily accumulated throughout the follow‐up period, 24.3% of the patients (95% CI 10.1%–36.3%) experienced PEG‐J‐related AE already within the first days after the PEG‐J insertion. Cox model revealed that older patients had higher probability of psychosis, PEG‐J‐ and device‐related AEs (p < .05, p < .05, and p = .02) and suggested increased recurrence risk in those with early PEG‐J and device‐related AEs. Despite relatively high incidence of AEs, HRQoL significantly increased in the follow‐up period (p < .0001). AEs related to LCIG treatment are common. Therefore, careful patient selection and monitoring throughout the treatment is recommended, especially in those with early side effects. Nevertheless, LCIG significantly improves HRQoL in advanced PD patients on a long term.

5 November 2022 in Human Brain Mapping
Verified
Journal Article
Open access
TRTomaž Rus
Tomaž Rus
MPMatej Perovnik
Matej Perovnik
AVAn Vo
An Vo
NNNha Nguyen
Nha Nguyen
CTChris Tang
Chris Tang
MTMaja Trošt
Maja Trošt
Behavioral variant of frontotemporal dementia (bvFTD) is common among young‐onset dementia patients. While bvFTD‐specific multivariate metabolic brain pattern (bFDRP) has been identified previously, little is known about its temporal evolution, internal structure, effect of atrophy, and its relationship with nonspecific resting‐state networks such as default mode network (DMN). In this multicenter study, we explored FDG‐PET brain scans of 111 bvFTD, 26 Alzheimer's disease, 16 Creutzfeldt‐Jakob's disease, 24 semantic variant primary progressive aphasia (PPA), 18 nonfluent variant PPA and 77 healthy control subjects (HC) from Slovenia, USA, and Germany. bFDRP was identified in a cohort of 20 bvFTD patients and age‐matched HC using scaled subprofile model/principle component analysis and validated in three independent cohorts. It was characterized by hypometabolism in frontal cortex, insula, anterior/middle cingulate, caudate, thalamus, and temporal poles. Its expression in bvFTD patients was significantly higher compared to HC and other dementia syndromes (p < .0004), correlated with cognitive decline (p = .0001), and increased over time in longitudinal cohort (p = .0007). Analysis of internal network organization by graph‐theory methods revealed prominent network disruption in bvFTD patients. We have further found a specific atrophy‐related pattern grossly corresponding to bFDRP; however, its contribution to the metabolic pattern was minimal. Finally, despite the overlap between bFDRP and FDG‐PET‐derived DMN, we demonstrated a predominant role of the specific bFDRP. Taken together, we validated the bFDRP network as a diagnostic/prognostic biomarker specific for bvFTD, provided a unique insight into its highly reproducible internal structure, and proved that bFDRP is unaffected by structural atrophy and independent of normal resting state networks loss.

12 January 2023 in European Journal of Neurology
Verified
Journal Article
Open access
TRTomaž Rus
Tomaž Rus
JMJernej Mlakar
Jernej Mlakar
LLLuka Ležaić
Luka Ležaić
AVAn Vo
An Vo
NNNha Nguyen
Nha Nguyen
MTMaja Trošt
Maja Trošt
Background and purpose: Although sporadic Creutzfeldt–Jakob disease (sCJD) is a rare cause of dementia, it is critical to understand its functional networks as the prion protein spread throughout the brain may share similar mechanisms with other more common neurodegenerative disorders. In this study, the metabolic brain network associated with sCJD was investigated and its internal network organization was explored.Methods: We explored 2‐[18F]fluoro‐2‐deoxy‐d‐glucose positron emission tomography (FDG‐PET) brain scans of 29 sCJD patients, 56 normal controls (NCs) and 46 other dementia patients from two independent centers. sCJD‐related pattern (CJDRP) was identified in a cohort of 16 pathologically proven sCJD patients and 16 age‐matched NCs using scaled subprofile modeling/principal component analysis and was prospectively validated in an independent cohort of 13 sCJD patients and 20 NCs. The pattern's specificity was tested on other dementia patients and its clinical relevance by clinical correlations. The pattern's internal organization was further studied using graph theory methods.Results: The CJDRP was characterized by relative hypometabolism in the bilateral caudate, thalami, middle and superior frontal gyri, parietal lobe and posterior cingulum in association with relative hypermetabolism in the hippocampi, parahippocampal gyri and cerebellum. The pattern's expression significantly discriminated sCJD from NCs and other dementia patients (p < 0.005; receiver operating characteristic analysis CJD vs. NCs area under the curve [AUC] 0.90–0.96, sCJD vs. Alzheimer's disease AUC 0.78, sCJD vs. behavioral variant of frontotemporal dementia AUC 0.84). The pattern's expression significantly correlated with cognitive, functional decline and disease duration. The metabolic connectivity analysis revealed inefficient information transfer with specific network reorganization.Conclusions: The CJDRP is a robust metabolic biomarker of sCJD. Due to its excellent clinical correlations it has the potential to monitor disease in emerging disease‐modifying trials.

7 December 2020 in Alzheimer's & Dementia
Verified
Journal Article
Open access
PDF file
MPMatej Perovnik
Matej Perovnik
TRTomaž Rus
Tomaž Rus
PTPetra Tomše
Petra Tomše
LJLuka Jensterle
Luka Jensterle
AEAndreja Emeršič
Andreja Emeršič
MTMaja Trost
Maja Trost
Background: Alzheimer’s disease (AD) is marked by accumulation of Aβ and tau protein causing neurodegeneration in the brain. AD represents a pathological and clinical continuum, ranging from mild cognitive impairment (MCI) to dementia. A specific metabolic imaging biomarker of AD ‐ Alzheimer’s disease‐related pattern (ADRP) has been previously identified from 2‐[18F]fluorodeoxyglucose positron emission tomography (2‐[18F]FDG‐PET) scans of clinically diagnosed AD patients, using scaled subprofile model based on principal component analysis (SSM/PCA) 1–3. However the clinical diagnosis may be wrong in substantial number of cases 4. We aimed to identify ADRP on patients with Alzheimer’s pathological changes in cerebrospinal (CSF) fluid and to validate it in an independent group of AD and other dementia patients and compare it to the original ADRP 1.Method: 2‐[18F]FDG‐PET scans from 20 AD1 and 20 normal controls (NC1) were used for pattern identification. Additional 110 scans were analyzed for validation: 68 from AD patients (37 AD2, 13 atypical clinical presentation AD (atAD), 18 MCI), 21 with frontotemporal dementia (FTD), 8 non‐AD MCI and 13 NC2 (Table 1). AD was defined with CSF biomarkers as: Aβ42 < 815 pg/ml, pTau > 60 pg/ml, tTau > 400 pg/ml. Topographic profile rating algorithm was used to prospectively calculate ADRP Z‐scores from subjects scans3. Mini‐mental state examination (MMSE) was performed in all patients.Results: ADRP was identified and voxel weights were found to be stable by bootstrap resampling, Figure 1. Pattern’s expression was significantly higher in AD1 than NC1 (p<0.001) and it strongly correlated (r=‐0.70) with MMSE. Pattern’s expression was also higher in AD2 than NC2 (p<0.001), MCI vs. NC2 (p<0.001), MCI vs. non‐AD MCI (p=0.02) and AD2 vs. FTD (p=0.02), Figure 2. Newly identified pattern moderately correlated (r=0.52) with the original one 1.Conclusions: We identified ADRP on a cohort of pathologically confirmed AD patients, which was not done before. ADRP has shown to be a reliable metabolic biomarker of AD related neurodegeneration. References: (1) Mattis,PJ. et al. Neurology 87,1925–33(2016); (2) Teune,LK. et al. Curr Alzheimer Res 11,725–32(2014); (3) Spetsieris,PG. & Eidelberg,D. Neuroimage 54,2899–914(2011); (4) Beach,TG. et al. J. Neuropathol. Exp. Neurol. 71,266–273(2012).

1 September 2020 in Parkinsonism & Related Disorders
Verified
Journal Article
Closed access
TRTomaž Rus
Tomaž Rus
PTPetra Tomše
Petra Tomše
LJLuka Jensterle
Luka Jensterle
LLLuka Ležaić
Luka Ležaić
CSClara Limbäck Stokin
Clara Limbäck Stokin
MTMaja Trošt
Maja Trošt